Choose a background: Click to apply background  Click to apply background  Click to apply background  Click to apply background  Click to apply background  Click to apply background  Click to apply background | Home Contact Sitemap
GT Pharma
(Pvt.) Ltd.
Leading Light for Life

In order to view this object you need Flash Player 9+ support!

Get Adobe Flash player

PRODUCTS

GT-FLOX
ED-3
GT-Cip-XL
GT CIP Suspension
Cheliron
Zegerid
Zegerid+
D-Prostol
Cagen-D
Mont Fex
K-Lot Paediatric 2mg/1ml


NEW RELEASES

Twitter Facebook

GT-FLOX

Fluoroquinolone Use in Paediatrics: Focus on Safety and Place in Therapy

(University of Missouri – Kansas City, Children’s Mercy Hospital, Kansas City, MO, USA, World Health Organization, 30-31 March 2010, Geneva, Switzerland)

Safety of Levofolxacin in infants and children less than five years and those > 12 years of age led the authors to recommend a dose of 10 mg/kg every 12 hours for infants and young children levofloxacin in children receiving oral and intravenous doses of the drug which suggested excellent oral bioavailability of the liquid formulation in pediatric patients.

The risk of Achilles tendon disorders associated with fluoroquinolone exposure was found to be relatively rare, with an overall excess risk of 3.2 cases per 1000 patients. The concomitant use of corticosteroids appears to substantially increase the risk.

This study involved greater than 6000 children < 19 years of age with history of fluoroquinolone exposure and a “control group” of children exposed to azithromycin, a macrolide antibiotic which does not have known effects on cartilage, tendons or joints. The calculated risk of tendon or joint disorders was found to be no different in the children treated with fluoroquinolones when compared to those prescribed azithromycin. 

Overall Clinical Success of GT-Flox
Community Acquired Pneumonia 96%
Pneumonia in Patients at Risk 87%
Uncomplicated AECB 95%
Complicated AECB 95%
Acute Sinusitis 87%
Complicated UTI and Pyelonephirtis 93%
Uncomplicated SSTI 97%
Complicated SSTI 86%
Intra Abdominal Infections 93%
Typhoid 97.5%

 



Home | The Company | Products | Quality Assurance | Production
Marketing & Sales | Contact Us | Misc. | Site Map

Choose a background: Click to apply background  Click to apply background  Click to apply background  Click to apply background  Click to apply background  Click to apply background  Click to apply background 
  Copyright 2011 © GT Pharma
Designed by Tech3188